Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2006

01-07-2006 | Review

PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes

Authors: S. Soyal, F. Krempler, H. Oberkofler, W. Patsch

Published in: Diabetologia | Issue 7/2006

Login to get access

Abstract

Data derived from several recent studies implicate peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) in the pathogenesis of type 2 diabetes. Lacking DNA binding activity itself, PGC-1α is a potent, versatile regulator of gene expression that co-ordinates the activation and repression of transcription via protein-protein interactions with specific, as well as more general, factors contained within the basal transcriptional machinery. PGC-1α is suggested to play a pivotal role in the control of genetic pathways that result in homeostatic glucose utilisation in liver and muscle, beta cell insulin secretion and mitochondrial biogenesis. This review focuses on the role of PGC-1α in glucose metabolism and considers how PGC-1α links cellular glucose metabolism, insulin sensitivity and mitochondrial function, and why defects in PGC-1α expression and regulation may contribute to the pathophysiology of type 2 diabetes in humans.
Appendix
Available only for authorised users
Literature
1.
Dietz WH (2004) Overweight in childhood and adolescence. N Engl J Med 350:855–857PubMed
2.
Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290:1884–1890PubMed
3.
O’Rahilly S, Barroso I, Wareham NJ (2005) Genetic factors in type 2 diabetes: the end of the beginning? Science 307:370–373PubMed
4.
McKenna NJ, O’Malley BW (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465–474PubMed
5.
Freedman LP (1999) Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97:5–8PubMed
6.
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829–839PubMed
7.
Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20:1868–1876PubMed
8.
Knutti D, Kaul A, Kralli A (2000) A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 20:2411–2422PubMed
9.
Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP (2000) Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. J Biol Chem 275:16302–16308PubMed
10.
Oberkofler H, Schraml E, Krempler F, Patsch W (2003) Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha. Biochem J 371:89–96PubMed
11.
Oberkofler H, Esterbauer H, Linnemayr V, Strosberg AD, Krempler F, Patsch W (2002) Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 277:16750–16757PubMed
12.
Delerive P, Wu Y, Burris TP, Chin WW, Suen CS (2002) PGC-1 functions as a transcriptional coactivator for the retinoid X receptors. J Biol Chem 277:3913–3917PubMed
13.
Huss JM, Kopp RP, Kelly DP (2002) Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem 277:40265–40274PubMed
14.
Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A (2003) The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha). J Biol Chem 278:9013–9018PubMed
15.
Wu Y, Delerive P, Chin WW, Burris TP (2002) Requirement of helix 1 and the AF-2 domain of the thyroid hormone receptor for coactivation by PGC-1. J Biol Chem 277:8898–8905PubMed
16.
Shiraki T, Sakai N, Kanaya E, Jingami H (2003) Activation of orphan nuclear constitutive androstane receptor requires subnuclear targeting by peroxisome proliferator-activated receptor gamma coactivator-1 alpha. A possible link between xenobiotic response and nutritional state. J Biol Chem 278:11344–11350PubMed
17.
Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK (2004) Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem 279:45139–45147PubMed
18.
Rhee J, Inoue Y, Yoon JC et al (2003) Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci USA 100:4012–4017PubMed
19.
Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA (2004) Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18:157–169PubMed
20.
Kallen J, Schlaeppi JM, Bitsch F et al (2004) Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha. J Biol Chem 279:49330–49337PubMed
21.
Puigserver P, Rhee J, Donovan J et al (2003) Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423:550–555PubMed
22.
Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM (2000) Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 6:307–316PubMed
23.
Kornblihtt AR (2004) Shortcuts to the end. Nat Struct Mol Biol 11:1156–1157PubMed
24.
Puigserver P, Adelmant G, Wu Z et al. (1999) Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286:1368–1371PubMed
25.
Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736PubMed
26.
Ichida M, Nemoto S, Finkel T (2002) Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1alpha). J Biol Chem 277:50991–50995PubMed
27.
Liu D, Zhang Z, Teng CT (2005) Estrogen-related receptor-gamma and peroxisome proliferator-activated receptor-gamma coactivator-1alpha regulate estrogen-related receptor-alpha gene expression via a conserved multi-hormone response element. J Mol Endocrinol 34:473–478PubMed
28.
Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM (2002) Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta ), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem 277:1645–1648PubMed
29.
Michael LF, Wu Z, Cheatham RB et al (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 98:3820–3825PubMed
30.
Shen H, Kan JL, Green MR (2004) Arginine–serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly. Mol Cell 13:367–376PubMed
31.
Ge K, Guermah M, Yuan CX et al (2002) Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature 417:563–567PubMed
32.
Patel NA, Kaneko S, Apostolatos HS et al (2005) Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem 280:14302–14309PubMed
33.
Auboeuf D, Honig A, Berget SM, O’Malley BW (2002) Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298:416–419PubMed
34.
Proudfoot NJ, Furger A, Dye MJ (2002) Integrating mRNA processing with transcription. Cell 108:501–512PubMed
35.
Orphanides G, Reinberg D (2002) A unified theory of gene expression. Cell 108:439–451PubMed
36.
Rocak S, Linder P (2004) DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 5:232–241PubMed
37.
Fairman ME, Maroney PA, Wang W et al (2004) Protein displacement by DExH/D ‘RNA helicases’ without duplex unwinding. Science 304:730–734PubMed
38.
Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PG, Katzenellenbogen BS (2003) Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). J Biol Chem 278:4628–4638PubMed
39.
Puigserver P, Rhee J, Lin J et al (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 8:971–982PubMed
40.
Knutti D, Kressler D, Kralli A (2001) Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci USA 98:9713–9718PubMed
41.
Fan M, Rhee J, St Pierre J et al (2004) Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev 18:278–289PubMed
42.
Moore ML, Park EA, McMillin JB (2003) Upstream stimulatory factor represses the induction of carnitine palmitoyltransferase-Ibeta expression by PGC-1. J Biol Chem 278:17263–17268PubMed
43.
Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113–118PubMed
44.
Nemoto S, Fergusson MM, Finkel T (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1alpha. J Biol Chem 280:16456–16460PubMed
45.
Shi T, Wang F, Stieren E, Tong Q (2005) SIRT3, a mitochondrial Sirtuin deacetylase, regulates mitochondrial function and thermogenesis in Brown adipocytes. J Biol Chem 280:13560–13567PubMed
46.
Baar K, Wende AR, Jones TE et al (2002) Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J 16:1879–1886PubMed
47.
Storey KB (2003) Mammalian hibernation. Transcriptional and translational controls. Adv Exp Med Biol 543:21–38PubMed
48.
Bryant NJ, Govers R, James DE (2002) Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 3:267–277PubMed
49.
Wu H, Kanatous SB, Thurmond FA et al (2002) Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296:349–352PubMed
50.
Terada S, Goto M, Kato M, Kawanaka K, Shimokawa T, Tabata I (2002) Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochem Biophys Res Commun 296:350–354PubMed
51.
Czubryt MP, McAnally J, Fishman GI, Olson EN (2003) Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci USA 100:1711–1716PubMed
52.
Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM (2003) An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci USA 100:7111–7116PubMed
53.
Akimoto T, Sorg BS, Yan Z (2004) Real-time imaging of peroxisome proliferator-activated receptor-gamma coactivator-1alpha promoter activity in skeletal muscles of living mice. Am J Physiol Cell Physiol 287:C790–C796PubMed
54.
Gleyzer N, Vercauteren K, Scarpulla RC (2005) Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol 25:1354–1366PubMed
55.
Wu Z, Puigserver P, Andersson U et al (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124PubMed
56.
Mootha VK, Handschin C, Arlow D et al (2004) Errα and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci USA 101:6570–6575PubMed
57.
Schreiber SN, Emter R, Hock MB et al (2004) The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 101:6472–6477PubMed
58.
Lin J, Wu H, Tarr PT et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801PubMed
59.
Herzig S, Long F, Jhala US et al (2001) CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413:179–183PubMed
60.
Daitoku H, Yamagata K, Matsuzaki H, Hatta M, Fukamizu A (2003) Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52:642–649PubMed
61.
Lin J, Wu PH, Tarr PT et al (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119:121–135PubMed
62.
Yoon JC, Puigserver P, Chen G et al (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131–138PubMed
63.
Nakae J, Park BC, Accili D (1999) Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 274:15982–15985PubMed
64.
Louet JF, Hayhurst G, Gonzalez FJ, Girard J, Decaux JF (2002) The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). J Biol Chem 277:37991–38000PubMed
65.
Du K, Herzig S, Kulkarni RN, Montminy M (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574–1577PubMed
66.
Koo SH, Satoh H, Herzig S et al (2004) PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10:530–534PubMed
67.
Himms-Hagen J (1990) Brown adipose tissue thermogenesis: interdisciplinary studies. FASEB J 4:2890–2898PubMed
68.
Tiraby C, Tavernier G, Lefort C et al (2003) Acquirement of brown fat cell features by human white adipocytes. J Biol Chem 278:33370–33376PubMed
69.
Wilson-Fritch L, Nicoloro S, Chouinard M et al (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281–1289PubMed
70.
Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 19:453–461PubMed
71.
Leone TC, Lehman JJ, Finck BN et al (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3:e101PubMed
72.
Yoon JC, Xu G, Deeney JT et al (2003) Suppression of beta cell energy metabolism and insulin release by PGC-1alpha. Dev Cell 5:73–83PubMed
73.
Zhang CY, Baffy G, Perret P et al (2001) Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105:745–755PubMed
74.
Krempler F, Esterbauer H, Weitgasser R et al (2002) A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 51:3331–3335PubMed
75.
Krauss S, Zhang CY, Scorrano L et al (2003) Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 112:1831–1842PubMed
76.
Zhang P, Liu C, Zhang C et al (2005) Free fatty acids increase PGC-1alpha expression in isolated rat islets. FEBS Lett 579:1446–1452PubMed
77.
Kitamura T, Nakae J, Kitamura Y et al (2002) The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110:1839–1847PubMed
78.
Nakae J, Biggs WH III, Kitamura T et al (2002) Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 32:245–253PubMed
79.
Russell AP, Feilchenfeldt J, Schreiber S et al (2003) Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes 52:2874–2881PubMed
80.
McGee SL, Hargreaves M (2004) Exercise and myocyte enhancer factor 2 regulation in human skeletal muscle. Diabetes 53:1208–1214PubMed
81.
Pilegaard H, Saltin B, Neufer PD (2003) Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol 546:851–858PubMed
82.
Richardson DK, Kashyap S, Bajaj M et al (2005) Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 280:10290–10297PubMed
83.
Ling C, Poulsen P, Carlsson E et al (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 114:1518–1526PubMed
84.
Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273PubMed
85.
Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466–8471PubMed
86.
Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142PubMed
87.
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671PubMed
88.
Lowell BB, Shulman GI (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307:384–387PubMed
89.
Esterbauer H, Oberkofler H, Krempler F, Patsch W (1999) Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62:98–102PubMed
90.
Pratley RE, Thompson DB, Prochazka M et al (1998) An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest 101:1757–1764PubMedCrossRef
91.
Perusse L, Rice T, Chagnon YC et al (2001) A genome-wide scan for abdominal fat assessed by computed tomography in the Quebec Family Study. Diabetes 50:614–621PubMed
92.
Stone S, Abkevich V, Hunt SC et al (2002) A major predisposition locus for severe obesity, at 4p15-p14. Am J Hum Genet 70:1459–1468PubMed
93.
Arya R, Duggirala R, Jenkinson CP et al (2004) Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. Am J Hum Genet 74:272–282PubMed
94.
Allayee H, de Bruin TW, Dominguez KM, Cheng LS et al (2001) Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension 38:773–778PubMed
95.
Ek J, Andersen G, Urhammer SA et al (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44:2220–2226PubMed
96.
Andrulionyte L, Zacharova J, Chiasson JL, Laakso M (2004) Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176–2184PubMed
97.
Andersen G, Wegner L, Jensen DP et al (2005) PGC-1{alpha} Gly482Ser polymorphism associates with hypertension among Danish whites. Hypertension 45:565–570PubMed
98.
Oberkofler H, Holzl B, Esterbauer H et al (2003) Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension 41:368–372PubMed
99.
Esterbauer H, Oberkofler H, Linnemayr V et al (2002) Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes 51:1281–1286PubMed
100.
Franks PW, Barroso I, Luan J et al (2003) PGC-1alpha genotype modifies the association of volitional energy expenditure with VO2max. Med Sci Sports Exerc 35:1998–2004PubMed
101.
Hara K, Tobe K, Okada T et al (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45:740–743PubMed
102.
Lacquemant C, Chikri M, Boutin P, Samson C, Froguel P (2002) No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasians. Diabetologia 45:602–603PubMed
103.
Oberkofler H, Linnemayr V, Weitgasser R et al (2004) Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 53:1385–1393PubMed
104.
Muller YL, Bogardus C, Pedersen O, Baier L (2003) A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 52:895–898PubMed
105.
Stumvoll M, Fritsche A, t’Hart LM et al (2004) The Gly482Ser variant in the peroxisome proliferator-activated receptor gamma coactivator-1 is not associated with diabetes-related traits in non-diabetic German and Dutch populations. Exp Clin Endocrinol Diabetes 112:253–257PubMed
106.
Rena G, Bain J, Elliott M, Cohen P (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 5:60–65PubMed
107.
De Souza CT, Araujo EP, Prada PO, Boschero AD, Velloso LA (2005) Short-term inhibition of peroxisome proliferator-activated receptor-γ coactivator-1α expression reverses diet-induced diabetes mellitus and hepatic steatosis in mice. Diabetologia 48:1860–1871PubMed
108.
Kim JH, Shin HD, Park BL et al (2005) Peroxisome proliferator-activated receptor gamma coactivator 1 alpha promoter polymorphisms are associated with early-onset type 2 diabetes mellitus in the Korean population. Diabetologia 48:1323–1330PubMed
109.
Pihlajamäki J, Kinnunen M, Ruotsalainen E et al (2005) Haplotypes of PPARGC1A are associated with glucose tolerance, body mass index and insulin sensitivity in offspring of patients with type 2 diabetes. Diabetologia 48:1331–1334PubMed
110.
The International HapMap Consortium (2003) The International HapMap Project. Nature 426:789–796
Metadata
Title
PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes
Authors
S. Soyal
F. Krempler
H. Oberkofler
W. Patsch
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0268-6

Other articles of this Issue 7/2006

Diabetologia 7/2006 Go to the issue

Article

Correlates of health-related quality of life in type 2 diabetes

Article

Is grand multiparity associated with an increased risk of dysglycaemia?

Letter

Comment to: Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–2438

Article

Prolactin regulatory element binding protein as a potential transcriptional factor for the insulin gene in response to glucose stimulation

Article

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

Article

Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits